| Symbol | PSNL |
|---|---|
| Name | PERSONALIS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical Specialities |
| Address | 6600 DUMBARTON CIRCLE, FREMONT, California, 94555, United States |
| Telephone | +1 650 - 752-1300 |
| Fax | — |
| — | |
| Website | https://www.personalis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001527753 |
| Description | Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions. Additional info from NASDAQ: |
Tachibana Aaron 🟡 adjusted position in 5.0K shares (1 derivative) of Personalis, Inc. (PSNL) at $14.00 Transaction Date: Jun 29, 2026 | Filing ID: 000007
Read more📋 AARON TACHIBANA (Officer) plans to sell 5K shares of PERSONALIS INC (at $13.02 each, total $65K) Filed: Jun 29, 2026 | ID: 006609
Read moreTachibana Aaron 🟡 adjusted position in 51.3K shares (2 derivative) of Personalis, Inc. (PSNL) at $13.18 ($1.4M) Transaction Date: Jun 26, 2026 | Filing ID: 000006
Read moreHall Christopher M 🟡 adjusted position in 100.0K shares (1 derivative) of Personalis, Inc. (PSNL) at $13.15 ($1.6M) Transaction Date: Jun 26, 2026 | Filing ID: 000004
Read moreNew Form 4/A - Personalis, Inc. <b>Filed:</b> 2026-06-11 <b>AccNo:</b> 0001231845-26-000002 <b>Size:</b> 5 KB
Read moreNew Form SCHEDULE 13D/A - Personalis, Inc. <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001805207-26-000003 <b>Size:</b> 40 KB
Read morePersonalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
Read moreTachibana Aaron 🟡 adjusted position in 40.0K shares (1 derivative) of Personalis, Inc. (PSNL) at $12.01 ($1.2M) Transaction Date: Jun 04, 2026 | Filing ID: 000005
Read more📋 AARON TACHIBANA (Officer) plans to sell 40K shares of Personalis, Inc. (at $10.78 each, total $431K) Filed: Jun 04, 2026 | ID: 005657
Read morePersonalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06225505 | Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) | Na | Triple Negative Breast Cancer | Recruiting | 2026-01-05 | 2031-08-03 | ClinicalTrials.gov |
| NCT06705361 | Ice Bag, TR Band, and Air Compression Effects on Radial Line Removal Outcomes i… | Na | Cardiac Disease | Not_Yet_Recruiting | 2024-11-25 | 2025-03-25 | ClinicalTrials.gov |
| NCT06230185 | CtDNA Based MRD Testing for NAC Monitoring in TNBC | — | TNBC - Triple-Negative Breast Cancer | Recruiting | 2023-11-09 | 2025-12-31 | ClinicalTrials.gov |
| NCT05414032 | Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HP… | Phase2 | Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | Recruiting | 2023-07-12 | 2028-07-01 | ClinicalTrials.gov |
| NCT05695976 | GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM | — | Glioblastoma | Suspended | 2023-04-18 | 2029-01-01 | ClinicalTrials.gov |
| NCT05197322 | NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer | Phase2 | Adenocarcinoma of the Colon | Recruiting | 2022-07-20 | 2029-07-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Transparent Radial Artery Band (Screw-Type) | Other | Approved | Cardiac Disease | NOT_YET_RECRUITING | NCT06705361 |
| 68Ga-FAPI-46-PET-CT | Other | Approved | Triple Negative Breast Cancer | RECRUITING | NCT06225505 |
| ctDNA monitoring | Other | Approved | Triple Negative Breast Cancer | RECRUITING | NCT06225505 |
| AZD2936 | Other | Phase PHASE2 | Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | RECRUITING | NCT05414032 |
| Pembrolizumab | Other | Phase PHASE2 | Adenocarcinoma of the Colon | RECRUITING | NCT05197322 |
| Pembrolizumab | Other | Phase PHASE2 | Adenocarcinoma of the Colon | RECRUITING | NCT05197322 |
| Transparent Radial Artery Band (Screw-Type) | DEVICE | Approved | Cardiac Disease | NOT_YET_RECRUITING | NCT06705361 |
| AZD2936 | BIOLOGICAL | Phase PHASE2 | Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | RECRUITING | NCT05414032 |